Recon: Moderna touts Omicron-targeted bivalent vaccine; EMA lists critical medicines against COVID-19

• Moderna says Omicron-targeted COVID shot shows better response (Reuters) (NYTimes) (STAT) (Moderna)
• Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival (NYTimes)
• Novavax COVID shot, aimed at vaccine skeptics, overwhelmingly backed by FDA panel (Reuters) (STAT)
• Sanofi's Dupixent gets U.S. approval to treat eczema in young children (Reuters)
• Eli Lilly’s new diabetes drug continues to show promise as an obesity treatment (CNBC)
• White House to cut funding for Covid testing to purchase vaccines for fall (NBC)
• Opinion: Prices for New Drugs Are Rising 20 Percent a Year. Congress Needs to Act. (NYTimes)
• Two new versions of Omicron are gaining ground in the U.S., according to C.D.C. estimates. (NYTimes)

• EMA adopts first list of critical medicines for COVID-19 (EMA) (List)
• One More EU MDR Notified Body In The Pipeline And Then A Gap (MedtechInsight)
• More than 1,000 monkeypox cases reported to WHO – briefing (Reuters)
• Innovation Passport  awarded Alnylam and its hypertension therapy (PharmaTimes)
• Novavax says COVID vaccine for U.S. to be manufactured by India's Serum (Reuters)
• Takeda teams with GSK, other drugmakers to track supplier emissions (Nikkei)

• DBV patches up prospects with phase 3 win in infants with peanut allergies (Fierce)
• Opinion: FDA user fee legislation needs to mitigate the pharmaceutical industry’s carbon pollution (STAT)
• After late-study endpoint switch, Aldeyra hails success of phase 3 dry eye disease trial (Fierce)
• Astellas joins Pfizer in emerging North Carolina hub, unveiling new $100M gene therapy manufacturing site (Endpoints)
• With eyes on first allogeneic CAR-T approval, Precision touts 100% response in 'small niche' population (Endpoints)
• For Rigel, a surprising placebo response spurs a PhIII fail, stock beating. But it's been here before (Endpoints)
• India Proposes OTC List But Clarity On Pricing, Switching Pathway Awaited (Pink Sheet)
• RA Capital backs a Philly biotech's $118M crossover as it aims to break into the hypertension space (Endpoints)
• New survey suggests many Black cancer patients aren't made aware of clinical trials (Endpoints)
• EQT's investment arm and Mubadala ink $3B deal for medical freight and storage company (Endpoints)
• German startup jumps into the hot radiopharma space with a former Ipsen compound as lead program (Endpoints)

• FDA mulls pilot program on alternative sterilization for medical devices (MedtechDive) (MedtechInsight)
• As monkeypox cases rise, BD pairs up with Spain-based CerTest for diagnostic (Fierce)
• FDA slaps Class I label on Medtronic latest heart pump recall (Fierce)
• GE Healthcare’s recall of ventilator batteries gets Class I label from FDA over device shutdown risk (MedtechDive)
• Expected Spread Of US OTC Diagnostics Could Change Consumers’ Health Care Behaviors (MedtechInsight)

• FTC opens investigation into largest PBMs' anticompetitive practices (Endpoints) (STAT)
• Bristol Myers settles anti-generic HIV drug scheme allegations for almost $11M (Endpoints)
• Georgia senator urges majority leader Chuck Schumer to follow through on insulin cap legislation (Endpoints)